Kawa Shigeyuki
Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Japan.
JMA J. 2019 Mar 4;2(1):11-27. doi: 10.31662/jmaj.2018-0017. Epub 2019 Jan 21.
Immunoglobulin G4-related disease (IgG4-RD) is a recently established systemic disease that is characteristically associated with elevated serum immunoglobulin G4 (IgG4) levels and believed to be caused by autoimmune mechanisms. The clinical features of IgG4-RD include (i) systemic distribution, (ii) imaging findings of swelling, nodules, and/or wall thickening, (iii) high serum IgG4 levels, (iv) abundant IgG4-bearing plasma cell infiltration and fibrosis in affected organs, (v) a favorable response to corticosteroid therapy, and (vi) coexistence with other IgG4-RD manifestations simultaneously or in a metachronous fashion. The concept of IgG4-RD was established based on the culmination of specific discoveries. Specifically, a close association between autoimmune pancreatitis (AIP) and high serum IgG4 levels, massive IgG4-bearing plasma cell infiltration in pancreatic tissues affected by AIP, and systemic other organ involvements in AIP with similar IgG4-bearing plasma cell features opened the gateway from AIP to IgG4-RD. The systemic distribution of IgG4-RD seems to be capable of affecting every organ, causing well-established members including AIP, lacrimal and salivary gland lesions such as Mikulicz's disease, respiratory diseases, sclerosing cholangitis, kidney diseases, and retroperitoneal fibrosis. IgG4-RD has been diagnosed worldwide, and international collaboration efforts on the disease have led to consensus publications on its nomenclature, pathology findings, and management approach. The algorithms developed for the comprehensive diagnostic criteria for IgG4-RD have remarkably increased detection sensitivity. Oral glucocorticoids are the first-line agents for remission induction, and certain patients with high disease activity may benefit from maintenance therapy afterwards. Originally, IgG4-RD had been considered reversible and to have a good prognosis; however, long-term afflictions sometimes result in transition to advanced-stage conditions with dysfunction and/or complicating malignancy. The immunological abnormalities in IgG4-RD have been reported in both innate and adaptive immune systems; however, it remains unclear whether IgG4 has a pathogenic role or a protective one in disease onset and progression.
免疫球蛋白G4相关性疾病(IgG4-RD)是一种最近被确认的全身性疾病,其特征是血清免疫球蛋白G4(IgG4)水平升高,被认为由自身免疫机制引起。IgG4-RD的临床特征包括:(i)全身性分布;(ii)影像学表现为肿胀、结节和/或管壁增厚;(iii)血清IgG4水平升高;(iv)受累器官中有大量含IgG4的浆细胞浸润和纤维化;(v)对糖皮质激素治疗反应良好;(vi)可同时或异时出现其他IgG4-RD表现。IgG4-RD的概念是基于一系列特定发现而确立的。具体而言,自身免疫性胰腺炎(AIP)与血清IgG4水平升高、AIP受累胰腺组织中大量含IgG4的浆细胞浸润以及AIP中具有相似含IgG4浆细胞特征的全身性其他器官受累之间的密切关联,为从AIP通向IgG4-RD打开了大门。IgG4-RD的全身性分布似乎能够影响各个器官,引发包括AIP、泪腺和唾液腺病变(如米库利奇病)、呼吸系统疾病、硬化性胆管炎、肾脏疾病以及腹膜后纤维化等已明确的病症。IgG4-RD已在全球范围内得到诊断,针对该疾病的国际合作努力已促成关于其命名、病理发现和管理方法的共识性出版物。为IgG4-RD综合诊断标准开发的算法显著提高了检测敏感性。口服糖皮质激素是诱导缓解的一线药物,某些疾病活动度高的患者后续可能从维持治疗中获益。最初,IgG4-RD被认为是可逆的且预后良好;然而,长期患病有时会导致病情进展至晚期,出现功能障碍和/或并发恶性肿瘤。IgG4-RD中的免疫异常在先天性和适应性免疫系统中均有报道;然而IgG4在疾病发生和进展中是具有致病作用还是保护作用仍不清楚。